Fedratinib reveals chemotherapeutic potential in esophageal squamous cell cancer.

ABSTRACT:

Background

Drug repurposing has emerged as a promising approach for discovering novel anticancer therapeutics. In this study, we systematically investigated the antitumor potential of fedratinib, a JAK2 inhibitor approved for myelofibrosis, against esophageal squamous cell carcinoma (ESCC) using integrated in vitro, in vivo, and patient-derived organoid (PDO) models. We further explored its underlying mechanisms of action.

Methods

ESCC cell lines (Eca109 and KYSE150) were treated with fedratinib to evaluate its effects on proliferation, migration, apoptosis, and cell cycle distribution. Molecular changes were examined using RT-qPCR and Western blot analyses. Antitumor efficacy was further validated in subcutaneous xenograft models and ESCC PDOs. Mechanistic inv

SUBMITTER: Luo M 

PROVIDER: S-EPMC12748225 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature